TauRx Therapeutics has announced the addition of 35 new clinical research centres across the US for its Alzheimer’s disease drug clinical trials.
The company is currently evaluating LMTX in Phase III clinical trials for Alzheimer’s disease. With the addition of new clinical research centres, more patients suffering from mild or moderate Alzheimer’s will have an opportunity to see if they qualify for participation in the company’s clinical trials.
With the expansion of study centres across the US, patients from Bennington, Vermont; Farmington Hills, Michigan; Waukesha, Wisconsin; and Creve Coeur, Missouri can also participate in the studies.
LMTX is TauRx Therapeutics’ second generation tau aggregation inhibitor. Currently, the company is measuring the effects of LMTX in Phase III clinical research studies on slowing and/or halting the progression of Alzheimer’s disease.
TauRx Therapeutics’ co-founder and chairman Dr Claude M Wischik said: "This compound is potentially a disease-modifying approach for treating Alzheimer’s, targeting the tangles of tau protein that develop in the brain, which are clearly linked to the progression of dementia.
"We are pleased to expand the number of research centres conducting our clinical trial to permit more people across the US to access our study.
"Only by participating in clinical studies such as ours, can we collectively, in partnership with those living with Alzheimer’s, help advance the essential research that can result in the development of new medicines for this terminal medical condition."
According to TauRx Therapeutics, LMTX offers a major advance over existing treatments for Alzheimer’s since its mode of action involves reducing of aggregated or misfolded tau proteins levels that are associated with the progressive neurodegeneration of Alzheimer’s disease.
LMTX has the same active ingredient ‘methylthioninium’ and same mode of action as TauRx’s first generation tau aggregation inhibitor ‘rember’. The company designed LMTX to have improved bioavailability and tolerability than rember.
TauRx Therapeutics’ LMTX family has also activity against synuclein aggregation, another protein misfolding disorder leading to Parkinson’s disease, offering potential for development in this indication as well.
Image: A PET scan of the brain of a person with Alzheimer’s disease. Photo: courtesy of LeadSongDog.